4.54

12.19% -0.63

After Hours: 4.58 0.04 +0.88%

Artelo Biosciences Inc (ARTL)

Overview News Price History Financials Discussions Forecast Stock Split

Artelo Biosciences Inc stock is traded at $4.54, with a volume of 255.41K. It is down -12.19% in the last 24 hours and up +533.02% over the past month. Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Previous Close:

$5.17

Open:

$4.93

24h Volume:

255.41K

Relative Volume:

0.36

Market Cap:

$2.49M

Revenue:

Net Income/Loss:

$-13.47M

P/E Ratio:

-0.1166

EPS:

-38.9215

Net Cash Flow:

$-8.38M

1W Performance:

+15.23%

1M Performance:

+533.02%

6M Performance:

-6.39%

1Y Performance:

-72.78%

1-Day Range:

$4.43

$4.93

1-Week Range:

$3.86

$15.73

52-Week Range:

$0.52

$19.91

Artelo Biosciences Inc Stock (ARTL) Company Profile

Name

Artelo Biosciences Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

858-925-7049

Address

505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA

Employee

Twitter

@ArteloBio

Next Earnings Date

2026-11-11

Latest SEC Filings

ARTL's Discussions on Twitter

Compare ARTL vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARTL Artelo Biosciences Inc	4.54	2.49M	0	-13.47M	-8.38M	-38.92
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-08-25	Upgrade	D. Boral Capital	Hold → Buy
Feb-12-21	Initiated	Ladenburg Thalmann	Buy

Artelo Biosciences Inc Stock (ARTL) Latest News

Sep 26, 2026

Premarket Movers: GCTK and PFSA Among Gainers, ARTL and BENF Among Losers - ChartMill

Sep 26, 2026

Sep 24, 2026

Keep an eye on the top gainers and losers in Thursday's session. - ChartMill

Sep 24, 2026

Wondering what's happening in today's pre-market session? - ChartMill

Sep 24, 2026

Artelo Biosciences (ARTL) Stock Rockets 206% After Obesity Treatment Patent Filing - Blockonomi

Sep 24, 2026

Sep 23, 2026

Top US Stock Movers for 2026-09-23: VSA Up 135.0%, JAGX Down 73.74% - ChartMill

Sep 23, 2026

Let's take a look at the stocks that are in motion in today's session. - ChartMill

Sep 23, 2026

After-Hours Movers on September 23, 2026: GCTK and VRME Among Gainers, BENF and BENFW Among Losers - ChartMill

Sep 23, 2026

Artelo Biosciences Soars Over 200% on Obesity Drug Patent Filing and Promising Data - finance.biggo.com

Sep 23, 2026

Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening? - Benzinga

Sep 23, 2026

Artelo Biosciences surges after obesity patent filing puts ART27.13 in focus - quiverquant.com

Sep 23, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Sep 23, 2026

Artelo Biosciences files new provisional patent application covering ART27.13 - TipRanks

Sep 23, 2026

Artelo files patent application for obesity treatment ART27.13 - Investing.com

Sep 23, 2026

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings - The Manila Times

Sep 23, 2026

Artelo Biosciences Files New Provisional Patent Application - GlobeNewswire

Sep 23, 2026

Sep 22, 2026

Artelo Biosciences reports positive ART27.13 results in neuropathic pain model - scanx.trade

Sep 22, 2026

Sep 19, 2026

Artelo Biosciences data supports ART26.12 for spinal cord injury pain - scanx.trade

Sep 19, 2026

Sep 16, 2026

Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug - Benzinga

Sep 16, 2026

Artelo Biosciences (ARTL) Reports Promising Weight-Loss Data Ami - GuruFocus

Sep 16, 2026

Artelo’s ART27.13 matches semaglutide weight loss in mice study - Investing.com

Sep 16, 2026

Artelo Biosciences announces results from nonclinical study of ART27.13 - TipRanks

Sep 16, 2026

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity - Yahoo! Finance Canada

Sep 16, 2026

Sep 11, 2026

Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com South Africa

Sep 11, 2026

Sep 08, 2026

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - ca.finance.yahoo.com

Sep 08, 2026

Sep 05, 2026

Artelo Biosciences Stock Price Forecast. Should You Buy ARTL? - StockInvest.us

Sep 05, 2026

Sep 03, 2026

Artelo Biosciences Inc. Warrant (ARTLW) Peer Comparison – Compare with Others - Value Research

Sep 03, 2026

Sep 02, 2026